Skip to main content
SpringerLink
Log in
Book cover

Clinical Pharmacology in Psychiatry pp 135–146Cite as

Selective Amine Oxidase Inhibitors: Basic to Clinical Studies and Back

  • Conference paper

Part of the book series: Psychopharmacology Series ((PSYCHOPHARM,volume 3))

Abstract

The monoamine oxidase (MAO)-inhibiting antidepressants, which have been in general clinical use in various parts of the world for the past 25 years, are all nonselective agents. They have marked effects on the metabolism of over 15 different monoamines, including major brain neurotransmitters (norepinephrine, dopamine, and serotonin) and on that of many other amines, which may act as co-transmitters, false transmitters, amine-releasing agents, or neuromodulators (e.g., tryptamine, tyramine, octopamine, and phenylethylamine).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Ask AL, Fagervall I, Jonze M, Kelder D, Nygren R, Ross SB (1984) Effects of acute and repeated administration of amiflamine on monoamine oxidase inhibition in the rat. Biochem Pharmacol 33: 2839–2847

    Article  PubMed  CAS  Google Scholar 

  • Ask AL, Fagervall I, Florvall L, Ross SB, Ytterborn S (1985) Inhibition of monoamine oxidase in 5-hydroxytryptaminergic neurones by substituted p-aminophenylalkylamines. Br J Pharmacol 85: 683–690

    PubMed  CAS  Google Scholar 

  • Aulakh CS, Cohen RM, Pradhan SN, Murphy DL (1983 a) Self-stimulation responses are altered following long-term but not short-term treatment with clorgyline. Brain Res 270: 383–386

    Google Scholar 

  • Aulakh CS, Cohen RM, McLellan C, Murphy DL (1983 b) Correlation of changes in α2-adrenoceptor number and locomotor responses to Clonidine following clorgyline discontinuation. Br J Pharmacol 80: 10–12

    Google Scholar 

  • Bieck P, Antonin KH, Jedrychowski M (1983) Monoamine oxidase inhibition in healthy volunteers by CGP 11305 A, a new specific inhibitor of MAO-A. Mod Probl Pharmacopsychiatry 19: 53–62

    PubMed  CAS  Google Scholar 

  • Buffoni F (1983) Biochemical pharmacology of amine oxidases. Trends Pharmacol Sci 4: 313–315

    Article  CAS  Google Scholar 

  • Campbell IC, Gallager DW, Hamburg MA, Tallman JF, Murphy DL (1985) Electrophysiological and receptor studies in rat brain: effects of clorgyline. Eur J Pharmacol 111: 355–364

    Article  PubMed  CAS  Google Scholar 

  • Casacchia M, Carolei A, Barba C, Rossi A (1984) Moclobemide (Ro 11-1163) versus placebo: a double-blind study in depressive patients. In: Tipton KF, Dostert P, Strolin Benedetti M (eds) Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors. Academic, London, pp 607–608

    Google Scholar 

  • Cawthon RM, Breakefield XO (1983) Differences in the structures of monoamine oxidases A and B in rat clonal cell lines. Biochem Pharmacol 32: 441–448

    Article  PubMed  CAS  Google Scholar 

  • Cohen RM, Campbell IC, Yamaguchi I, Pickar D, Kopin I J, Murphy DL (1982 a) Cardiovascular changes in response to selective monoamine oxidase inhibition in the rat. Eur J Pharmacol 80: 155–160

    Google Scholar 

  • Cohen RM, Ebstein RP, Daly JW, Murphy DL (1982 b) Chronic effects of a monoamine oxidase-inhibiting antidepressant: decreases in functional alpha-adrenergic autoreceptors precede the decrease in norepinephrine-stimulated cyclic adenosine 3′: 5′-monophosphate systems in rat brain. J Neurosci 2: 1588–1595

    Google Scholar 

  • Cohen RM, Pickar D, Garnett D, Lipper S, Gillin JC, Murphy DL (1982 c) REM sleep suppression induced by selective monoamine oxidase inhibitors. Psychopharmacology (Berlin) 78: 137–140

    Google Scholar 

  • Cohen RM, Aulakh CS, Murphy DL (1983) Long-term clorgyline treatment antagonizes the eating and motor function responses to m-chlorophenylpiperazine. Eur J Pharmacol 94: 175–179

    Article  PubMed  CAS  Google Scholar 

  • Da Prada M, Kettler R, Burkard WP, Haefely WE (1984) Moclobemide, an antidepressant with short-lasting MAO-A inhibition: brain catecholamines and tyramine pressor effects in rats. In: Tipton KF, Dostert P, Strolin Benedetti M (eds) Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors. Academic, London, pp 137–154

    Google Scholar 

  • Demarest KT, Smith DJ, Azzaro AJ (1980) The presence of the type A form of monoamine oxidase within nigrostriatal dopamine-containing neurons. J Pharmacol Exp Ther 215: 461–468

    PubMed  CAS  Google Scholar 

  • Donnelly CH, Murphy DL (1977) Substrate and inhibitior-related characteristics of human platelet monoamine oxidase. Biochem Pharmacol 26: 853–858

    Article  PubMed  CAS  Google Scholar 

  • Donnelly DH, Richelson E, Murphy DL (1976) Properties of monoamine oxidase in mouse neuroblastoma NIE-115 cells. Biochem Pharmacol 27: 959–963

    Google Scholar 

  • Felner AE, Waldmeier PC (1979) Cumulative effects of irreversible MAO inhibitors in vivo. Biochem Pharmacol 28: 995–1002

    Article  PubMed  CAS  Google Scholar 

  • Fowler CJ, Mantle TJ, Tipton KF (1982) The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline. Biochem Pharmacol 31: 3555–3561

    Article  PubMed  CAS  Google Scholar 

  • Fuller RW (1968) Influence of substrate in the inhibition of rat liver and brain monoamine oxidase. Arch Int Pharmacodyn Ther 174: 32–37

    PubMed  CAS  Google Scholar 

  • Fuller RW (1978) Selectivity among monoamine oxidase inhibitors and its possible importance for development of antidepressant drugs. Prog Neuropsychopharmacol Biol Psychiatry 2: 303–311

    CAS  Google Scholar 

  • Garrick NA, Murphy DL (1980) Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain. Psychopharmacology (Berlin) 72: 27–33

    Article  CAS  Google Scholar 

  • Garrick NA, Murphy DL (1982) Monoamine oxidase type A: differences in selectivity towards levo-norepinephrine compared to serotonin. Biochem Pharmacol 31: 4061–4066

    Article  PubMed  CAS  Google Scholar 

  • Garrick NA, Scheinin M, Chang WH, Linnoila M, Murphy DL (1984) Differential effects of clorgyline on catecholamine and indoleamine metabolites in the cerebrospinal fluid of rhesus monkeys. Biochem Pharmacol 33: 1423–1427

    Article  PubMed  CAS  Google Scholar 

  • Garrick NA, Seppala T, Linnoila M, Murphy DL (1985 a) Rhesus monkey cerebrospinal fluid amine metabolite changes following treatment with the reversible monoamine oxidase type- A inhibitor cimoxatone. Psychopharmacology (Berlin) 86: 265–269

    Google Scholar 

  • Garrick NA, Seppala T, Linnoila M, Murphy DL (1985 b) The effects of amiflamine on cerebrospinal fluid amine metabolites in the rhesus monkey. Eur J Pharmacol 110: 1–9

    Google Scholar 

  • Goridis C, Neff NH (1971) Evidence for a specific monoamine oxidase associated with sympathetic nerves. Neuropharmacology 10: 557–564

    Article  PubMed  CAS  Google Scholar 

  • Hall DWR, Logan BW, Parsons GH (1969) Further studies on the inhibition of monoamine oxidase by M + B 9302 (clorgyline): I. Substrate specificity in various mammalian species. Biochem Pharmacol 18: 1447–1454

    Google Scholar 

  • Herd JA (1969) A new antidepressant - M and B 9302. A pilot study and double-blind controlled trial. Clin Trials 6: 219–225

    Google Scholar 

  • Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17: 1285–1297

    Article  PubMed  CAS  Google Scholar 

  • Kettler R, Keller HH, Bonetti EP, Wyss PC, Da Prada M (1985) Ro 16-6491: a new highly selective and reversible MAO-B inhibitor. J Neurochem 44: S94

    Article  Google Scholar 

  • Knoll J (1978) The possible mechanisms of action of (—)deprenyl in Parkinson’s disease. J Neural Transm 43: 117–198

    Article  Google Scholar 

  • Knoll J, Ecseri Z, Kelemen K, Nievel J, Knoll B (1965) Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer. Arch Int Pharmacodyn Ther 155: 154–164

    PubMed  CAS  Google Scholar 

  • Kuhn DM, Murphy DL, Youdim MBH (1986) Physiological and clinical aspects of monoamine oxidase. In: Mondori B (ed) Monoamine oxidases. CRC Publications Press, New York (in press)

    Google Scholar 

  • Larsen JK, Mikkelsen PL, Holm P (1984) Moclobemide (Ro 11-1163) in the treatment of major depressive disorder. A randomized clinical trial. In: Tipton KF, Dostert P, Strolin Benedetti M (eds) Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors. Academic, London, p 609

    Google Scholar 

  • Levitt P, Pintar JE, Breakefield XO (1982) Immunocytochemieal demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc Natl Acad Sci USA 79: 6385–6389

    Article  PubMed  CAS  Google Scholar 

  • Linnoila M, Karoum F, Potter WZ (1982) Effect of low-dose clorgyline on 24-h urinary monoamine excretion in patients with rapidly cycling bipolar affective disorder. Arch Gen Psychiatry 39: 513–516

    PubMed  CAS  Google Scholar 

  • Lipper S, Murphy DL, Slater S, Buchsbaum MS (1979) Comparative behavioral effects of clorgyline and pargyline in man: a preliminary evaluation. Psychopharmacology (Berlin) 62: 123–128

    Article  CAS  Google Scholar 

  • Major LF, Murphy DL, Lipper S, Gordon E (1979) Effects of clorgyline and pargyline on deaminated metabolites of norepinephrine, dopamine and serotonin in human cerebrospinal fluid. J Neurochem 32: 229–231

    Article  PubMed  CAS  Google Scholar 

  • McDonald IA, Lacoste JM, Bey P, Paltreyman MG, Zreika M (1985) Enzyme-activated irreversible inhibitors of monoamine oxidase phenylallylamine structure-activity relationships. J Med Chem 28: 186–193

    Article  PubMed  CAS  Google Scholar 

  • Mendelewicz J, Youdim MBH (1983) L-Deprenyl, a selective monoamine oxidase type-B inhibitor, in the treatment of depression: a double-blind evaluation. Br J Psychiatry 142: 508–511

    Article  Google Scholar 

  • Mendis N, Pare CMB, Sandler M, Glover V, Stern M (1981) Is the failure of L-deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect. Psychopharmacology (Berlin) 73:87–90

    Google Scholar 

  • Murphy DL (1978) Substrate-selective monoamine oxidases: inhibitor, tissue, species and functional differences. Biochem Pharmacol 27: 1889–1893

    Google Scholar 

  • Murphy DL, Donelly CH, Richelson E, Fuller RW (1978) N-Substituted cyclopropylamines as inhibitors of MAO A and B forms. Biochem Pharmacol 27: 1767–1769

    Google Scholar 

  • Murphy DL, Donnelly CH, Richelson E (1976) Substrate and inhibitor-related characteristics of monoamine oxidase in C 6 rat glial cells. J Neurochem 26: 1231–1235

    Article  PubMed  CAS  Google Scholar 

  • Murphy DL, Lipper S, Campbell IC, Major LF, Slater SL, Buchsbaum MS (1979) Comparative studies of MAO-A and MAO-B inhibitors in man. In: Singer TP, von Korff RW, Murphy DL (eds) Monoamine oxidase: structure, function and altered functions. Academic, New York, pp 457–475

    Google Scholar 

  • Murphy DL, Pickar D, Jimerson D, Cohen RM, Garrick NA, Karoum F, Wyatt RJ (1981) Biochemical indices of the effects of selective MAO inhibitors (clorgyline, pargyline and deprenyl) in man. In: Usdin E, Dahl SG, Gram LF, Lingjaerde O (eds) Clinical pharmacology in psychiatry: Neuroleptic and antidepressant research. Macmillan, London, pp 307–316

    Google Scholar 

  • Murphy DL, Garrick NA, Aulakh CS, Cohen RM (1984) New contributions from basic science to understanding the effects of monoamine oxidase inhibiting antidepressants. J Clin Psychiatry 45: 37–43

    PubMed  CAS  Google Scholar 

  • Murphy DL, Tamarkin L, Sunderland T, Garrick NA, Cohen RM (1986) Human plasma melatonin is elevated during treatment with the monoamine oxidase inhibitors clorgyline and tranylcypromine but not deprenyl. Psychiatry Res 17: 119–127

    Article  PubMed  CAS  Google Scholar 

  • Palfreyman MG, McDonald I, Zreika M, Fozard JR (1984) The prodrug approach to brain selective MAO inhibition. In: Tipton KF, Dostert P, Strolin Benedetti M (eds) Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors. Academic, London, pp 561–562

    Google Scholar 

  • Roy BF, Murphy DL, Lipper S, Siever L, Alterman IS, Jimerson D, Lake CR, Cohen RM (1986) Cardiovascular effects of the selective monoamine oxidase-inhibiting antidepressant clorgyline: correlations with clinical responses and changes in catecholamine metabolism. J Clin Psychopharmacol (in press)

    Google Scholar 

  • Siever LJ, Uhde TW, Murphy DL (1981) Possible sensitization of alpha2-adrenergie receptors by chronic monoamine oxidase inhibitor treatment in psychiatric patients. Psychiatry Res 6: 293–302

    Article  Google Scholar 

  • Singer TP, von Korff RW, Murphy DL (eds) (1979) Monoamine oxidase: structure, function and altered functions. Academic, New York

    Google Scholar 

  • Stefanis CN, Alevizos B, Papadimitriou GN (1984) Controlled clinical study of moclobemide (Ro 11-1163), a new MAO inhibitor, and desipramine in depressive patients. In: Tipton KF, Dostert P, Strolin Benedetti M (eds) Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors. Academic, London, pp 377–392

    Google Scholar 

  • Strolin Benedetti M, Dostert P (1985) Stereochemical aspects of MAO interactions: reversible and selective inhibitors of monoamine oxidase. Trends Pharmacol Sci 6: 249–251

    Google Scholar 

  • Sunderland T, Mueller EA, Cohen RM, Jimerson DC, Pickar D, Murphy DL (1985) Tyramine pressor sensitivity changes during deprenyl treatment. Psychopharmacology (Berlin) 86: 432–437

    Article  CAS  Google Scholar 

  • Tipton KF, Dostert P, Strolin Benedetti M (eds) (1984) Monoamine oxidase and disease: prospects for therapy with reversible inhibitors. Academic, London

    Google Scholar 

  • Waldmeier PC, Felner AE, Maitre L (1981) Long-term effects of selective MAO inhibitors on MAO activity and amine metabolism. In: Youdim MBH, Paykel ES (eds) Monoamine oxidase inhibitors. The state of the art. Wiley, New York, pp 87–102

    Google Scholar 

  • Westlund KN, Denney RM, Kochersperger LM, Rose RM, Abell CW (1985) Distinct monoamine oxidase A and B populations in primate brain. Science 230: 181–183

    Article  PubMed  CAS  Google Scholar 

  • Wheatley D (1970) Comparative trial of a new monoamine oxidase inhibitor in depression. Br J Psychiatry 117: 547

    Article  Google Scholar 

  • Yang HYT, Neff NH (1974) The monoamine oxidases of brain: selective inhibition with drugs and the consequences for the metabolism of the biogenic amines. J Pharmacol Exp Ther 733–740

    Google Scholar 

  • Youdim MBH, Banerjee DK, Pollard HB (1984) Isolated chromaffin cells from adrenal medulla contain primarily monoamine oxidase B. Science 224: 619–621

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section on Clinical Neuropharmacology, Laboratory of Clinical Science, National Institute of Mental Health, NIH Clinical Center, 10-3D41 Bethesda, MD, 20892, USA

    D. L. Murphy, T. Sunderland, N. A. Garrick & C. S. Aulakh

  2. Section on Clinical Brain Imaging, Laboratory of Cerebral Metabolism, National Institute of Mental Health, NIH Clinical Center, 10-4N317 Bethesda, MD, 20892, USA

    R. M. Cohen

Authors
  1. D. L. Murphy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Sunderland
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. A. Garrick
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. S. Aulakh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. M. Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pharmacology, Institute of Medical Biology, University of Tromsø School of Medicine, N-9001, Tromsø, Norway

    Svein G. Dahl Cand Real, Dr. Philos. (Professor of Pharmacology) (Professor of Pharmacology)

  2. Department of Clinical Pharmacology, School of Medicine, Odense University, DK-5000, Odense C, Denmark

    Lars F. Gram MD (Professor of Clinical Pharmacology) (Professor of Clinical Pharmacology)

  3. Clinical Neuroscience Branch, National Institute of Mental Health, Building 10, Room 4N214, 20205, Bethesda, MD, USA

    Steven M. Paul MD (Chief) (Chief)

  4. Section on Clinical Psychopharmacology, Laboratory of Clinical Science, Building 10, National Institute of Mental Health, 20205, Bethesda, MD, USA

    William Z. Potter MD, PhD (Chief) (Chief)

Rights and permissions

Reprints and permissions

Copyright information

© 1987 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Murphy, D.L., Sunderland, T., Garrick, N.A., Aulakh, C.S., Cohen, R.M. (1987). Selective Amine Oxidase Inhibitors: Basic to Clinical Studies and Back. In: Dahl, S.G., Gram, L.F., Paul, S.M., Potter, W.Z. (eds) Clinical Pharmacology in Psychiatry. Psychopharmacology Series, vol 3. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71288-3_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-71288-3_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-71290-6

  • Online ISBN: 978-3-642-71288-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation